PAINS management: an open source model to eliminate nuisance compounds
High-throughput screening (HTS) technologies have enabled the routine testing of millions of compounds towards the identification of novel ‘hit’ molecules for therapeutic targets. Oftentimes in this drug discovery process, however, compounds that show promising activity in primary screens show no activity during subsequent hit qualification or progression efforts.